Inflammation has a significant influence in the development of colorectal cancer (CRC) ([@bib31]; [@bib45]). Patients with chronic inflammatory bowel disease, such as ulcerative colitis and Crohn\'s disease, have an increased risk of developing CRC ([@bib11]; [@bib49]). Preventive effect of NSAIDs on the development of CRC has been shown in epidemiological studies ([@bib36]) and also in a randomised placebo-controlled trial in HNPCC ([@bib4]). Immune cells also contribute to the immunosurveillance, and high-grade peri- and intratumoral inflammatory cell infiltration is an independent indicator of an improved survival in CRC ([@bib20]; [@bib14]; [@bib38]). Moreover, systemic inflammatory markers like modified Glasgow prognostic score (mGPS) and blood neutrophil/lymphocyte ratio have established prognostic value in CRC ([@bib37]).

Cytokines are key regulators of immune responses in cancer. They can modulate tumour growth and microenvironment by mediating interactions between cancer cells and infiltrating inflammatory cells. On the basis of their function, cytokines can be grouped into anti- or proinflammatory cytokines, chemokines, and growth factors. Moreover, the classification into Th1 and Th2 cytokines is of importance. In general, Th1-type cytokines, e.g., interleukin (IL)-12, IL-15, and interferon gamma (IFN-*γ*), contribute to cellular immune reactions considered essential for an effective response against tumour cells, whereas Th2-type cytokines, e.g., IL-4, IL-5, IL-10, and IL-13, may suppress the tumour-specific immune response ([@bib12]; [@bib8]).

The development of CRC is accompanied by alterations in cytokine production, which is thought to polarise from Th1 into Th2 along the colorectal adenoma--carcinoma sequence ([@bib8]). Increased serum cytokine concentrations, e.g., elevated levels of IL-8 ([@bib48]), IL-6 ([@bib21]), and platelet-derived growth factor (PDGF) ([@bib2]) have been reported in CRC patients compared with healthy individuals, and certain cytokines and chemokines, such as IL-6 and VEGF, are considered to have prognostic value ([@bib6]; [@bib9]; [@bib21]). One of the limitations of the previous studies examining serum inflammatory markers has been that they have focused on the levels of one or few cytokines at a time. However, relative alterations in cytokine levels can have substantial effects in the immune functions ([@bib7]). Therefore, it is likely that an analysis of extensive set of cytokines would provide more accurate information on the tumour-related immunological responses, thus also bringing out the importance of individual cytokines on the immune response against CRC.

Tumour stage (TNM classification) is the most important prognostic factor in CRC ([@bib34]), and 5-year survival rate varies from 90% in stage I tumours to \<10% in advanced stage IV tumours ([@bib30]). To reduce mortality, it is essential to develop diagnostic tools for the early detection of cancer, which could be easily adapted to clinical use. At the moment, stool tests are neither very sensitive nor specific, and colonoscopy is a time-consuming and costly screening method ([@bib43]). Several serum markers have been assessed in the diagnostics of the disease, but none have been adapted to routine use so far ([@bib43]).

The aim of this study was to evaluate the pattern of alterations in the serum cytokine levels in CRC patients compared with controls. Accordingly, we analysed serum levels of 27 cytokines and chemokines from a series of 148 newly diagnosed CRC patients, and healthy controls matched for age and gender. An additional goal was to see whether the patterns of the serum cytokines in CRC could provide information of tumour stage.

Materials and methods
=====================

Patients and controls
---------------------

This prospective study was introduced to all newly diagnosed CRC patients operated in Oulu University Hospital between April 2006 and January 2010 (*n*=344), of which a total of 148 patients were both eligible for the study and had signed informed consent to participate. Control serum samples were obtained from age- and sex-matched healthy voluntary blood donors (Finnish Red Cross, Oulu, Finland; *n*=36, age \<65 years) and cataract surgery patients (Oulu University Hospital; *n*=50, age ⩾65 years). Patients and controls with earlier or simultaneously diagnosed other malignant diseases were excluded. Owing to the strict regulations in blood donation, other exclusion criteria for blood donor controls included, e.g., the absence of acute infections, trauma or operation during the preceding 4 months, chronic diseases like coronary artery disease, stroke or cancer, and organ transplantation. Study design was accepted by the Ethical Committee of Oulu University Hospital (58/2005, 184/2009).

Clinical details of patients and controls were acquired from the clinical records and by a questionnaire. Data on recurrences by the 24-month follow-up visit was collected in August 2012. Preoperative staging of CRC was done by whole-body CT-scan and the local staging of rectal cancer was done by MRI. Patients with T3 or T4 rectal tumours received preoperative radiotherapy or chemoradiotherapy (RT/CRT, *n*=32). To avoid confounding and to model the situation before the diagnosis of the disease, only those CRC patients who did not receive preoperative RT/CRT (*n*=116) were included in this study.

For the histopathological analysis, samples from the surgical specimens were fixed in 10% buffered formalin solution, embedded in paraffin, and 5-*μ*m sections were stained with haematoxylin and eosin. TNM 6 ([@bib41]) was used in staging and WHO classification in grading ([@bib15]). On an average, 15 lymph nodes were examined (median 12, interquartile range 8--19, range 0--62). Peritumoral inflammatory reaction was evaluated according to a two-tiered Klintrup--Mäkinen classification, where peritumoral inflammatory cell reaction was estimated to be low-grade when the peritumoral inflammatory cells formed no or patchy infiltrate that did not cause destruction of invading cancer cells at the invasive margin, and high-grade when inflammatory cells formed band-like or cuff-like peritumoral tumour-destructive infiltrate at the invasive margin ([@bib20]).

Collection and analysis of serum samples
----------------------------------------

Blood samples from patients and controls were obtained in the morning after fasting for 12 h. The samples were centrifuged, and serum was stored at −70 °C until further analysis. Serum cytokine concentrations were analysed with Bio-Plex Pro Human pre-manufactured 27-Plex Cytokine Panel (Bio-Rad, Hercules, CA, USA). The pre-manufactured cytokine panel included 27 cytokines: IL-1*β*, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IFN-*γ*, tumour necrosis factor alpha, IFN-*γ*-induced protein 10 kDa (IP-10, CXCL10), monocyte chemotactic protein-1 (MCP-1, CCL2), macrophage inflammatory protein-1*α* (MIP-1*α*, CCL3), MIP-1*β* (CCL4), regulated upon activation, normal T-cell expressed, and secreted (CCL5), eotaxin (CCL11), granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, fibroblast growth factor basic, PDGF, subtype BB (PDGF-BB), and vascular endothelial growth factor A. The assay conditions were controlled, standardized and pre-optimized to ensure optimal repeatability and reproducibility of the assays according to the manufacturer\'s instructions. The assay kits were all from the same lot, which allows better control of inter-assay variability. For the analyses, the samples were diluted in the appropriate sample matrix 1 : 2. The beads were incubated overnight with the samples. A minimum of 50 events (beads) were collected for each analyte, and the concentrations calculated from the standard curves on the basis of median fluorescence intensities. BioPlex Manager Software 4.1 (Bio-Rad) was utilised in calculating the concentrations.

Out of the 27 analytes, 13 cytokines (IL-1ra, IL-4, IL-6, IL-7, IL-8, IL-9, IL-12, IFN-*γ*, IP-10, MCP-1, MIP-1*β*, eotaxin, and PDGF-BB) with three (1.5%) or fewer values outside the assay working range were included in this study. The other 14 cytokines (IL-1*β*, IL-2, IL-5, IL-10, IL-13, IL-15, IL-17, fibroblast growth factor basic, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, MIP-1*α*, regulated upon activation, normal T-cell expressed, and secreted, tumour necrosis factor, and VEGF) were excluded from this study because of having 20 (10%) or more of the values below or above the assay working range, which would not enable an examination as a continuous variable ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Statistical analyses
--------------------

Normally distributed continuous variables are presented as mean (s.d.), whereas other continuous variables are presented as median (interquartile range). Statistical significances of the differences in serum cytokine levels between the different study groups and age, sex, stage, grade, inflammatory reaction, and BMI categories were analysed by Mann--Whitney *U*-test or Kruskal--Wallis test. Univariate correlations are presented as Pearson\'s correlation coefficients after a logarithmic transformation of the variables with positive skewness. A logistic regression model was generated to evaluate the potential of serum cytokine profile in discriminating the CRC patients from the controls. For the model, the cytokine levels were logarithmically transformed to improve the goodness of fit. Backward stepwise approach was used to restrict the model to the five most predictive cytokines. The predictive power of the final model was evaluated by receiver operating characteristics analysis, and the goodness of fit of the model was tested with the Hosmer--Lemeshow statistic, where a nonsignificant probability value indicates good fit. The logistic regression model for the presence of nodal metastases was also constructed using the backward stepwise method. Multiple linear regression was used in stage-adjusted assessment of the associations between serum cytokines and patient age. The statistical analyses were carried out using statistical analysis software PASW Statistics 18 (IBM, Chicago, IL, USA). In all the tests, a two-tailed, exact *P* value \<0.05 was considered statistically significant.

Results
=======

Univariate analyses
-------------------

The characteristics of 116 CRC patients and 86 healthy controls are shown in [Table 1](#tbl1){ref-type="table"}, and their preoperative serum cytokine levels are summarised in [Table 2](#tbl2){ref-type="table"}. The levels of IL-6, IL-7, IL-8, and PDGF-BB were increased, and the levels of MCP-1 were decreased in patients compared with controls. Also Th1 cytokines IL-12 and IFN-*γ* showed a tendency towards increased values in CRC.

Age and gender
--------------

For seven of the thirteen cytokines (PDGF-BB, IL-1ra, IL-7, IL-8, IL-9, IFN-*γ*, and MIP-1*β*), the serum levels were higher in patients younger than 65 years compared with older patients ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Only IP-10 levels were higher in patients aged 65 or older. The associations were mainly similar when age was studied as a continuous variable and correlation coefficients were calculated ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Serum levels were similar in females and males ([Supplementary TABLE 4](#sup1){ref-type="supplementary-material"}), except for eotaxin, the levels of which were higher in male compared with female patients (*P*=0.017). There were no significant differences in cytokine levels between patients in different body mass index groups (data not shown).

Clinicopathological parameters
------------------------------

The patients with proximal tumour had higher serum IP-10 compared with patients having distal colon or rectal cancer (*P*=0.032; [Supplementary Table 5](#sup1){ref-type="supplementary-material"}). WHO grade 3 tumours yielded higher IL-1ra, IL-6, and IL-8 levels compared with grade 1 or 2 tumours ([Table 3](#tbl3){ref-type="table"}). Significant alterations of cytokine levels were also seen when assessing the effect of TNM stage ([Table 4](#tbl4){ref-type="table"}), as the levels of IL-1ra and especially IL-8 had an association with high-stage disease. Deeper local invasion (*T*) was associated with increased serum levels of IL-6 (*P*=0.015), IL-8 (*P*=9.28E−5), and MCP-1 (*P*=0.023; [Supplementary Table 6](#sup1){ref-type="supplementary-material"}), and the levels of IL-8 were also higher in the presence of lymph-node metastases (*P*=0.017; [Supplementary Table 7](#sup1){ref-type="supplementary-material"}). The patients with distant metastases (M1) had higher serum levels of IL-1ra (*P*=0.008), IL-4 (*P*=0.033), IL-6 (*P*=0.011), IL-7 (*P*=0.008), IL-8 (*P*=3.14E−5), MCP-1 (*P*=0.016), and PDGF-BB (*P*=0.010) compared with patients without metastases (M0; [Supplementary Table 8](#sup1){ref-type="supplementary-material"}). Serum cytokine levels were associated with other systemic inflammation markers. Patients with higher modified Glasgow prognostic score had higher serum levels of IL-1ra, IL-6, IL-7, IL-8, IL-9, IL-12, IFN-*γ*, IP-10, MCP-1, MIP-1*β*, and PDGF-BB ([Supplementary Table 9](#sup1){ref-type="supplementary-material"}). High blood neutrophil/lymphocyte ratio was associated with higher serum levels of IL-1ra, IL-6, IL-7, IL-8, and IL-12, MCP-1, and PDGF-BB, and high CRP was associated with higher levels of IL-1ra, IL-6, IL-7, IL-8, IL-12, and eotaxin ([Supplementary Table 10](#sup1){ref-type="supplementary-material"}). Klintrup--Mäkinen classification showed a statistical trend with the serum IL-8 levels (*P*=0.08, Mann--Whitney *U*-test). More detailed analyses of local inflammatory cell reaction were considered to be out of the scope of the current study.

Multivariate analyses
---------------------

We generated a logistic regression model to evaluate the potential of serum cytokine profile in discriminating the CRC patients from the controls and to assess the mutual relationships of the differences observed in the univariate analyses. Certain cytokine values from three subjects were unreadable, and the model was based on 115 of 116 CRC patients and 84 of 86 controls.

The final model is presented in [Table 5](#tbl5){ref-type="table"}. It consists of the five most predictive cytokines chosen using the backward stepwise method. As in the univariate analyses, high IL-8 and IL-6, as well as low MCP-1, were associated with CRC. Interestingly, also low IL-1ra and IP-10 were associated with CRC, although these cytokines showed no difference between CRC patients and healthy controls in the univariate analyses. Hosmer-Lemeshow test for goodness-of-fit of the model indicated a good calibration (*χ*^2^=11.1, probability value=0.195). A receiver operating characteristics analysis for the model ([Figure 1](#fig1){ref-type="fig"}) yielded an area under curve of 0.890 (95% confidence interval, CI 0.845--0.934), which denotes an excellent discriminatory capability. Receiver operating characteristics curves were also obtained separately to all the cytokines included in the regression model, and the area under curves were the following: IL-1ra, 0.541 (95% CI 0.461--0.622); IL-6, 0.724 (95% CI 0.654--0.793); IL-8, 0.769 (95% CI 0.703--0.834); IP-10, 0.510 (95% CI 0.429--0.592); and MCP-1, 0.634 (95% CI 0.557--0.711).

Next, we generated a logistic regression model for discriminating patients with nodal metastases from patients without nodal metastases. Using the backward stepwise method, the model was restricted to the four most predictive cytokines because of a smaller number of positive cases than in the model used to separate patients from controls. In this model, low IFN-γ (OR 0.09, 95% CI 0.005--1.65, *P*=0.105) and IP-10 (OR 0.11, 95% CI 0.015--0.85, *P*=0.034) and high IL-8 (OR 9.4, 95% CI 1.5--58.3, *P*=0.016) and IL-1ra (OR 8.3, 95% CI 0.8--84.5, *P*=0.074) were associated with lymph-node metastases. A small amount of M1 cases (*n*=18) did not enable a construction of a sensible logistic regression model for the presence of distant metastases.

Regression models were also used to adjust the differences observed in univariate analyses for potential confounding factors. Several potential confounding factors were tested, and in our material, adjusting for BMI, sex, and the age of the patients did not influence the results of the univariate analyses (data not shown). Tumour grade correlated with stage, but small numbers of grade 3 (*n*=14) tumours did not allow us to construct a regression model to confirm confounding by that. Most of the negative correlations between serum cytokine levels and patient age were found to be a result of younger patients being more likely to have a metastasised disease, as age correlated only positively with IP-10 and negatively with PDGF-BB when the correlations were adjusted for stage using multiple linear regression ([Supplementary Table 11](#sup1){ref-type="supplementary-material"}).

Recurrence analysis
-------------------

Owing to the short follow-up at the moment, we were not able to perform a complete 60-month survival analysis. Instead, we carried out a 24-month recurrence analysis, which included 79 (68.1%) of 116 patients. Of the 116 patients, 22 (19.0%) were excluded because they underwent a palliative operation, and 15 (12.9%) were excluded because they did not have the 24-month follow-up data available. Recurrences were observed in 17 patients (21.5%). None of the studied cytokine markers had a statistically significant association with recurrences ([Supplementary Table 12](#sup1){ref-type="supplementary-material"}). However, a longer follow-up is needed, and also neutrophil/lymphocyte ratio, modified Glasgow prognostic score, and Klintrup--Mäkinen classification for local general inflammatory infiltrate ([Supplementary Table 13](#sup1){ref-type="supplementary-material"}) lacked a significant association with recurrences in this limited follow-up despite having an established prognostic value.

Discussion
==========

Cytokines and chemokines form a complex network of regulatory proteins, and often several cytokines are required to synergize to bring about an optimal effect ([@bib7]). To our knowledge, this is so far the most extensive study on serum cytokine and chemokine alterations in CRC. The method used in this study offers an opportunity to study relative changes of cytokine levels, allowing analysing the shifts in the immune balance occurring in patients with CRC. In this study, we generated a logistic regression model that showed an excellent ability to discriminate patients from the controls, and yielded information that may prove useful for the development of clinical applications for screening, diagnosis, staging, and even for the follow-up of CRC.

In univariate analyses, CRC patients had increased serum levels of PDGF-BB, IL-6, IL-7, and IL-8, and decreased levels of MCP-1. The increases in serum PDGF-BB, IL-6, and IL-8 levels in CRC have been reported earlier ([@bib48]; [@bib2]; [@bib21]). Increase of IL-7 levels and decrease of MCP-1 levels in CRC represent novel findings of this study. Previously, IL-7 levels have been reported to be increased in early-stage prostate cancer as compared with benign prostate hyperplasia ([@bib27]), and decreased MCP-1 levels have been described in gastric cancer ([@bib47]). Of these five cytokines, PDGF-BB has a prominent role in cell proliferation, cell migration, and angiogenesis ([@bib16]). IL-6 is a pleiotropic cytokine with a variety of functions, including interaction between acute and chronic inflammation, inducing B-lymphocyte responses, and acute-phase functions like pyrogenic effect ([@bib29]), whereas IL-7 is considered to be an important haematopoietic cytokine having a role in the generation of both T and B lymphocytes ([@bib24]). The primary function of IL-8 is to recruit neutrophils during acute inflammation, while MCP-1 is chemoattractant for monocytes ([@bib50]).

The knowledge of the cancer-specific functions of cytokines and chemokines is still limited. In CRC, IL-6 has been reported to increase the proliferation and invasiveness of cancer cells and promote tumour angiogenesis ([@bib21]). Also IL-8 has been suggested to have a multifunctional role in CRC progression, which possibly involves enhancing the survival of cancer cells and regulating adhesion and invasion, in addition to recruiting neutrophils ([@bib39]; [@bib51]). These suggested functions correspond to our observation of both IL-6 and IL-8 having an association with a metastasised disease. Higher levels of IL-7 in CRC seen in this study is an interesting finding, as IL-7 enhances the responses to immunisation, especially to weak or low-affinity antigens common for cancer ([@bib26]; [@bib5]). Monocyte chemoattractant MCP-1 has been shown to be overexpressed in several solid tumours, and it is thought to be responsible for acquiring tumour-associated macrophages, which in most tumours present with an anti-inflammatory phenotype ([@bib25]).

The role of tumour-associated macrophages in CRC is controversial. Most studies have indicated that peritumoral macrophages have a favourable effect on CRC prognosis, suggesting their polarisation towards M1 phenotype ([@bib20]; [@bib13]). On the contrary, intratumoral macrophages in CRC have been shown to be correlated with invasion and lymph-node metastases, and in general with more aggressive behaviour, which allows a suggestion that intratumoral macrophages in CRC are polarised towards M2 phenotype ([@bib32]; [@bib19]). In colon, increased MCP-1 expression has been observed in colorectal adenomas in relation to normal epithelium, and it has also been related to an increased tumour-associated macrophage accumulation within tumour tissue and to an advancing stage ([@bib44]; [@bib1]). It should be noted, however, that the increase of MCP-1 in colorectal adenoma and CRC tissue has been observed in relation to the non-neoplastic mucosa of CRC or adenoma patients, not to the normal mucosa obtained from healthy controls. In our study, serum MCP-1 concentrations are increased by advancing stage, yet in all CRC patients, we detected lower mean serum concentrations of MCP-1 than in controls. In an earlier report examining serum MCP-1 levels, 14% of CRC patients had lower MCP-1 value than the minimum value of any of the healthy volunteers, although no statistically significant difference between these two study groups was observed ([@bib46]).

According to our results, the absolute levels of cytokines generally increase in CRC, but there are also alterations in the relative cytokine levels indicating a shift in the balance of the immune system. Our logistic regression model revealed a relative decrease in the levels of serum IL-1ra and IP-10 in CRC, besides the increases in serum IL-6 and IL-8 and the decrease in serum MCP-1, which were also seen in univariate analyses. In this model, decreased IL-1ra/IL-6 ratio in CRC might indicate a decreased systemic anti-inflammatory response against the tumour. Similarly, increased levels of neutrophil chemoattractant IL-8 relative to monocyte chemoattractants IP-10 and MCP-1 might depict an orientation towards a granulocyte response, although mononuclear cells are considered to be the main contributors to restricting cancer growth ([@bib20]). However, the actions of most cytokines and chemokines are pleiotropic ([@bib7]), and, e.g., IP-10, a chemokine secreted by several cell types in response to IFN-*γ*, is antiangiogenic besides possessing a leucocyte chemoattractant function ([@bib23]; [@bib42]).

Our findings corroborate earlier observations that serum cytokine levels in CRC have only minor association with age and gender ([@bib18]; [@bib40]). In our study, the levels of PDGF-BB, IL-1ra, IL-7, IL-8, IL-9, IFN-*γ*, and MIP-1*β* were slightly higher and IP-10 levels were lower in younger patients in univariate analysis, but younger patients more often presented with a metastatic disease. After adjusting for disease stage, the only significant correlations between serum cytokines and patient age were lower IP-10 and higher PDGF levels in the younger patients. The only difference we observed between males and females was higher eotaxin levels in the male patients. Biology of this difference is unknown at present, but it could offer a new aspect for studying gender-related differences of CRC.

Proximal and distal CRCs are different regarding their pathogenesis and many clinical and pathological characteristics, as well as in their behaviour. Proximal CRC is more frequent in female patients, presents more often with MSI and increased numbers of tumour-infiltrating lymphocytes, and also a greater proportion of Lynch syndrome-associated CRCs occur in the proximal colon ([@bib17]). On this basis, we expected that the differences of the proximal and distal CRCs would be reflected in the cytokine profile, but the only difference we found was slightly elevated levels of IP-10 in proximal colon cancer compared with distal colon and rectal cancer.

The levels of IL-1ra, IL-6, and IL-8 were found to be significantly higher in patients with poorly differentiated tumours than in those with well- or moderately-differentiated tumours. However, the levels of these three cytokines were also among those most dependent on the tumour stage, which could confound the result. Nevertheless, similar association of serum IL-6 and IL-8 and poor differentiation has been reported earlier in CRC ([@bib18]), and poorly differentiated and undifferentiated CRCs have been demonstrated to have up to 20-fold activity in *IL-6* gene ([@bib3]), suggesting that the increased serum levels observed could be related to an increased IL-6 production by the poorly differentiated cancer cells.

The alterations in the levels of major Th1 (IL-12, IFN-*γ*) and Th2 (IL-4) cytokines was one of our interests, as a shift towards Th2 cytokine response has been proposed to occur in the development of CRC ([@bib33]; [@bib8]). We could not demonstrate a clear polarisation of the systemic cytokine levels towards Th2 in CRC, as our CRC patients showed a trend for increased levels of both Th2 (IL-4) and Th1 (IL-12 and IFN-*γ*) cytokines. Instead, a Th2-oriented cytokine milieu -- evidenced by an increase in IL-4 in the absence of significant alterations in IL-12 and IFN-*γ* -- was associated with a metastatic disease. Thus, rather than being characteristic to CRC, shift of Th1/Th2 balance towards Th2 seems to be related to the progression of cancer. In tissue level, local Th1-type immune response typically shows high densities of tumour-infiltrating lymphocytes and is associated with better survival ([@bib35]; [@bib28]). An association of Th1 response with prognostically significant antitumour activity is further supported by our regression model, where high IFN-*γ* associated with the absence of nodal metastases. Therefore, we believe that assessment of Th1/Th2 balance may help to identify CRC patients with a shift of cytokine levels towards Th2, resulting in an ineffective immune response and unfavourable prognosis. Such patients could be reasonable subjects for more intensive or tailored treatment, including immunomodulatory therapy ([@bib31]). However, at this point, the follow-up time in our prospective material is not long enough, and it remains to be seen, whether serum cytokine profile could add prognostic information to other systemic inflammation-based markers like neutrophil/lymphocyte ratio or modified Glasgow prognostic score ([@bib37]).

Majority of CRC deaths could be prevented by sensitive screening methods. At the moment, stool tests are neither very sensitive nor specific, and colonoscopy is a time-consuming and costly method ([@bib43]). Carcinoembryonic antigen is a widely used serum biomarker for CRC follow-up, but its sensitivity and specificity in the detection of CRC is low ([@bib10]; [@bib43]). As cytokines and chemokines are involved in most systemic and local inflammatory diseases, it is unlikely that determination of any single cytokine could be used as a diagnostic or a follow-up marker for CRC. Instead, by examining changes in multiple cytokines, it may be possible to detect more specific 'cytokine footprints\' for different inflammatory and neoplastic diseases. For example, a promising result based on a multiplexed cytokine immunoassay in identifying lung cancer has been reported recently ([@bib22]). In our study, measurements covering several essential cytokines enabled us to generate a logistic regression model -- a serum cytokine profile -- which achieved an excellent accuracy in discriminating CRC patients from healthy controls with an area under curve of 0.890 in the receiver operating characteristics analysis. This observation supports the potential of cytokine determinations as a screening or diagnostic tool. Still, our study has also limitations, as we did not have comparison groups of patients with inflammatory or infectious diseases and the logistic regression model was specifically fitted to our material. Therefore, our results and approach need to be confirmed by subsequent studies with independent study populations, and in studies including subjects with inflammatory conditions and gastrointestinal symptoms.

In conclusion, CRC is characterised by broad and complex alterations in serum cytokine and chemokine levels, including increased PDGF-BB, IL-6, IL-7, and IL-8 and decreased MCP-1. Our study highlights the benefits of analysing the serum cytokine levels as a group to observe relative expression level changes. Future studies are needed to compare the alterations between serum cytokine levels and individual inflammatory cell response to reveal immune reaction patterns in CRC, as well as to evaluate the specificity of the alterations of the cytokine profile in CRC in relation to other inflammatory disorders and neoplasms.
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![A receiver operating characteristics curve for serum cytokine/chemokine profile in discriminating CRC patients from healthy controls. The profile achieved an excellent discriminatory capability. Several probability cutoff values were tested, and the sensitivities and specificities were calculated: cutoff 0.349 (sensitivity 0.930, specificity 0.607), cut-off 0.500 (sensitivity 0.826, specificity 0.738), cut-off 0.545 (sensitivity 0.809, specificity 0.821), and cut-off 0.690 (sensitivity 0.687, specificity 0.952). Abbreviations: AUC=area under curve; CI=confidence interval.](bjc2012456f1){#fig1}

###### Characteristics of the patients and controls

                                        **CRC patients (*****n*****=116)**   **Healthy controls (*****n*****=86)**
  ------------------------------------- ------------------------------------ ---------------------------------------
  Age, mean (s.d.)                      67.9 (11.2)                          67.3 (10.6)
  BMI, mean (s.d.)                      26.6 (4.5)                           27.4 (3.6)
  White blood cell count, mean (s.d.)   6.9 (2.1)                            6.9 (1.5)
                                                                              
  *Gender*                                                                    
   Male                                 58 (50%)                             45 (52.3%)
   Female                               58 (50%)                             41 (47.7%)
                                                                              
  *Preoperative RT/CRT*                                                      
   Yes                                  0 (0%)                                
   No                                   116 (100%)                            
                                                                              
  *Tumour location*                                                          
   Proximal colon                       49 (42.2%)                            
   Distal colon                         27 (23.3%)                            
   Rectum                               40 (34.5%)                            
                                                                              
  *WHO grade*                                                                
   Grade 1                              16 (13.8%)                            
   Grade 2                              86 (74.1%)                            
   Grade 3                              14 (12.1%)                            
                                                                              
  *TNM stage (*n*=115)*                                                      
   Stage I                              19 (16.5%)                            
   Stage II                             46 (40.0%)                            
   Stage III                            32 (27.8%)                            
   Stage IV                             18 (15.7%)                            

Abbreviations: BMI=body mass index; CRC=colorectal cancer; RT/CRT=radiotherapy or chemoradiotherapy; s.d.=standard deviation.

###### Serum cytokine and chemokine levels in colorectal cancer patients compared with healthy controls

             **CRC patients (*****n*****=116)**   **Healthy controls (*****n*****=86)**    
  ---------- ------------------------------------ --------------------------------------- ---------
  IL-1ra     63.8 (37.9--98.2)                    62.7 (43.8--75.9)                       0.296
  IL-4       0.88 (0.75--1.13)                    0.83 (0.72--0.99)                       0.127
  IL-6       4.89 (3.44--8.92)                    3.57 (2.62--4.54)                       1.3E−7
  IL-7       5.53 (3.99--7.46)                    4.71 (3.43--5.61)                       2.9E−4
  IL-8       12.3 (9.13--18.1)                    8.30 (6.94--10.5)                       7.3E−11
  IL-9       9.18 (5.57--13.9)                    7.39 (6.06--12.0)                       0.221
  IL-12      30.1 (15.7--40.9)                    23.9 (14.3--34.6)                       0.068
  IFN-*γ*    31.7 (24.1--43.4)                    28.7 (23.1--34.4)                       0.068
  Eotaxin    132.6 (91.0--181.4)                  136.5 (108.8--211.3)                    0.081
  IP-10      918.5 (670.2--1212.3)                885.8 (694.0--1352.7)                   0.869
  MCP-1      16.6 (10.8--23.7)                    22.3 (15.2--32.2)                       0.002
  MIP-1*β*   64.6 (50.2--81.9)                    69.6 (55.8--87.1)                       0.118
  PDGF-BB    8595.5 (5570.3--11352.0)             7623.5 (5312.4--9330.2)                 0.041

Abbreviations: CRC=colorectal cancer; IFN-*γ*=interferon gamma; IL=interleukin; IP-10=IFN-*γ*-induced protein 10 kDa; IQR=interquartile range; MCP-1=monocyte chemotactic protein-1; MIP-1*β*=macrophage inflammatory protein-1*β*; PDGF-BB=platelet-derived growth factor, subtype BB.

*P* values are for Mann--Whitney *U*-test.

###### Serum cytokine levels of CRC patients in WHO Grades 1--3

             **Grade 1 (*****n*****=16)**   **Grade 2 (*****n*****=86)**   **Grade 3 (*****n*****=14)**    
  ---------- ------------------------------ ------------------------------ ------------------------------ -------
  IL-1ra     38.4 (31.1--85.5)              65.8 (41.6--98.4)              80.8 (54.1--122.3)             0.032
  IL-4       0.88 (0.60--1.04)              0.86 (0.75--1.17)              1.00 (0.84--1.14)              0.210
  IL-6       4.08 (2.51--4.55)              4.98 (3.46--8.71)              7.87 (4.03--21.3)              0.016
  IL-7       4.90 (3.04--7.42)              5.53 (4.26--7.62)              5.92 (3.83--7.05)              0.501
  IL-8       9.10 (8.15--13.4)              12.4 (9.64--16.9)              18.8 (11.5--29.4)              0.020
  IL-9       5.86 (3.35--11.5)              9.27 (6.12--14.3)              12.0 (7.55--20.4)              0.064
  IL-12      26.1 (13.4--31.3)              32.5 (15.7--41.0)              29.4 (12.8--55.3)              0.524
  IFN-*γ*    26.3 (17.4--35.3)              32.4 (24.9--45.9)              31.8 (25.4--48.6)              0.077
  Eotaxin    121.7 (79.2--176.1)            141.2 (103.2--181.8)           109.1 (66.5--194.2)            0.558
  IP-10      864.5 (706.8--1481.6)          924.0 (651.3--1160.4)          1041.5 (670.3--2561.9)         0.425
  MCP-1      13.0 (10.1--19.5)              17.2 (10.5--25.5)              17.0 (12.9--24.5)              0.286
  MIP-1*β*   52.7 (43.5--69.3)              65.2 (51.1--81.9)              64.8 (47.2--91.4)              0.312
  PDGF-BB    8485.0 (2958.5--12079.4)       8569.9 (5796.2--12406.0)       8687.1 (7206.7--10056.2)       0.772

Abbreviations: CRC=colorectal cancer; IFN-*γ*=interferon gamma; IL=interleukin; IP-10=IFN-*γ*-induced protein 10 kDa; IQR=interquartile range; MCP-1=monocyte chemotactic protein-1; MIP-1*β*=macrophage inflammatory protein-1*β*; PDGF-BB=platelet-derived growth factor, subtype BB.

*P* values are for Kruskal--Wallis test.

###### Serum cytokine levels of CRC patients in different TNM stages

             **Stage I (*****n*****=19)**   **Stage II (*****n*****=46)**   **Stage III (*****n*****=32)**   **Stage IV (*****n*****=18)**    
  ---------- ------------------------------ ------------------------------- -------------------------------- ------------------------------- ---------
  IL-1ra     47.9 (33.0--89.1)              60.0 (36.2--91.3)               63.6 (36.6--98.2)                92.7 (75.9--107.0)              0.039
  IL-4       0.90 (0.64--1.08)              0.82 (0.71--1.17)               0.85 (0.74--1.02)                1.06 (0.91--1.12)               0.176
  IL-6       4.33 (3.17--6.59)              4.69 (3.38--9.24)               4.73 (3.10--8.59)                7.72 (4.79--12.6)               0.055
  IL-7       5.56 (3.37--7.59)              5.03 (3.65--7.40)               5.39 (4.06--7.38)                7.04 (5.87--9.21)               0.060
  IL-8       9.20 (8.09--12.5)              12.1 (8.97--18.8)               12.1 (9.43--14.2)                20.4 (14.4--60.1)               6.99E−5
  IL-9       8.00 (3.75--20.4)              8.63 (4.94--13.6)               7.79 (4.67--13.1)                10.9 (8.57--20.4)               0.298
  IL-12      24.6 (15.7--31.5)              31.6 (15.4--40.3)               33.0 (11.8--47.5)                30.3 (17.1--42.4)               0.662
  IFN-*γ*    33.9 (20.1--45.1)              31.5 (22.0--46.1)               29.0 (25.2--40.1)                32.3 (28.9--43.4)               0.573
  Eotaxin    167.9 (72.2--184.4)            142.8 (106.3--178.2)            124.9 (92.0--171.5)              129.4 (78.0--182.8)             0.644
  IP-10      885.2 (722.4--1605.4)          901.7 (654.6--1270.5)           893.8 (585.4--1130.3)            1015.9 (770.1--1461.1)          0.600
  MCP-1      14.1 (11.0--23.7)              16.9 (9.36--27.0)               14.8 (10.8--18.9)                24.3 (14.9--41.2)               0.073
  MIP-1*β*   66.1 (42.2--85.6)              62.3 (47.3--82.2)               63.8 (52.3--80.6)                72.8 (50.7--82.8)               0.900
  PDGF-BB    8246.5 (4762.9--12395.9)       8474.3 (4689.3--11502.6)        8150.2 (5859.2--10066.8)         10495.6 (8115.8--15109.7)       0.085

Abbreviations: CRC=colorectal cancer; IFN-*γ*=interferon gamma; IL=interleukin; IP-10=IFN-*γ*-induced protein 10 kDa; IQR=interquartile range; MCP-1=monocyte chemotactic protein-1; MIP-1*β*=macrophage inflammatory protein-1*β*; PDGF-BB=platelet-derived growth factor, subtype BB.

*P* values are for Kruskal--Wallis test.

###### Logistic regression model for predicting colorectal cancer

             **Coefficient**    **OR**  **95% CI**        ***P*****-value**
  ---------- ----------------- -------- ----------------- -------------------
  IL-1ra     −3.76              0.023   0.002--0.225      0.0011
  IL-6       3.95                52.1   4.29--632.4       0.0019
  IL-8       9.07               8665.4  201.1--373433.1   2.3E−6
  IP-10      −3.21              0.041   0.0052--0.315     0.0022
  MCP-1      −3.53              0.029   0.0057--0.149     2.1E−5
  Constant   9.28                                          

Abbreviations: CI=confidence interval; IL=interleukin; IP-10=IFN-*γ*-induced protein 10 kDa; MCP-1=monocyte chemotactic protein-1; OR=odds ratio.

The data shown are on the basis of the 115 colorectal cancer patients and 84 controls. All the cytokine/chemokine levels were logarithmically transformed. A receiver operating characteristics curve for the model is presented in [Figure 1](#fig1){ref-type="fig"}.

[^1]: These authors contributed equally to this work.
